Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate

Immunocore Holdings plc

Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.
Three Phase 3 trials enrolling in melanoma (TEBE-AM, PRISM-MEL-301, ATOM); first topline data expected 2026.
New autoimmune candidate IMC-U120AI (CD1a x PD1) for atopic dermatitis; CTA planned 2026.
Initial HIV Phase 1 multiple ascending dose data for IMC-M113V expected Q1 2025.
Travis Coy appointed EVP, CFO and Head of Corporate Development (ex-Eli Lilly).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.